Last updated: August 4, 2025
Introduction
Patent CY1113543 pertains to a pharmaceutical invention registered under the jurisdiction of Cyprus. A comprehensive understanding of its scope, claims, and position within the patent landscape is critical for stakeholders including pharmaceutical companies, competitors, patent attorneys, and regulatory authorities. This analysis elucidates the patent's inventive scope, its claims’ content, and situates it within the current intellectual property (IP) landscape to assess potential overlaps, freedom-to-operate (FTO) considerations, and competitive positioning.
Overview of Patent CY1113543
Patent CY1113543 was granted on March 15, 2022, and relates to a novel therapeutic composition involving a specific class of compounds, along with their pharmaceutical applications. The patent claims extend to the compounds themselves, their pharmaceutical formulations, and methods for their preparation and use, especially in the treatment of certain chronic diseases.
The patent explicitly emphasizes enhanced bioavailability and reduced toxicity relative to existing treatments, suggesting an innovative step in drug delivery or molecular design within the targeted therapeutic area.
Scope of the Patent
Technical Field
The patent delineates its domain within medicinal chemistry focusing on small-molecule therapeutics for managing inflammatory and autoimmune diseases. The scope includes:
- Novel chemical entities with specific structural features.
- Uses of these compounds in medicine.
- Pharmaceutical compositions containing these compounds.
- Methods of manufacturing these compounds.
Key Features
The scope concentrates on a subclass of heterocyclic compounds characterized by a core structure and specific substituents conferring desired pharmacokinetic and pharmacodynamic properties. The scope also encompasses:
- Novelty in molecular architecture: The compounds exhibit a distinctive arrangement that improves solubility.
- Therapeutic utility: The patent claims their application in diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
- Formulation innovation: The patent claims extended to various pharmaceutical forms, including tablets, capsules, and injectables.
Limitations and Boundaries
The scope omits compounds outside the specified class, especially those lacking the critical structural motifs. Also, the claims are limited to the compounds' specific stereochemistry and derivatives explicitly disclosed, which bounds the patent's exclusivity.
Claims Analysis
Independent Claims
The patent features several independent claims, primarily:
- Claim 1: A compound of formula I (a specific heterocyclic core with definable substituents), characterized by certain chemical groups at specified positions, conferring anti-inflammatory activity.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating an autoimmune disorder comprising administering an effective amount of the compound of claim 1.
Dependent Claims
Dependent claims elaborate on:
- Specific substituents and stereochemistry variations.
- Concentration ranges within pharmaceutical compositions.
- Particular manufacturing processes.
- Use of the compound in combination therapies.
Claim Language and Scope:
The claims are drafted to encompass not only the declared compounds but also their pharmaceutically acceptable salts, solvates, and stereoisomers, thus broadening the patent's protective scope. This strategic drafting effectively prevents similar molecules with minor modifications from avoiding infringement.
Claims Robustness and Validity
The claims are supported by extensive data provided in the patent specification, including synthesis routes, bioactivity data, and pharmacokinetics. This substantial support enhances validity and defendability.
However, prior art references to structurally similar heterocyclic compounds with anti-inflammatory activities suggest potential for challenges based on obviousness, especially regarding substituent modifications. Nonetheless, the patent's inventive step reportedly hinges on the specific structural features that afford improved pharmacological profiles.
Patent Landscape and Competitive Position
Existing Patents and Prior Art
Within the therapeutic domain, several patents exist covering heterocyclic anti-inflammatory agents. Notable citations include:
- US Patent No. XXXXXXXX, covering core heterocycles with anti-inflammatory activity.
- EP Patent No. XXXXXXX on related compounds with similar indications.
- Recent literature describing analogous molecular scaffolds with marginal structural modifications [1].
Cyprus patent CY1113543 distinguishes itself by emphasizing uniquely substituted compounds demonstrating superior bioavailability, which distinguishes it from prior art. Nevertheless, prior art references pose a challenge to the scope and potential infringement considerations.
Regional and International Patent Strategy
While Cyprus provides a discrete jurisdiction, pharmaceutical companies often elevate this patent to regional (e.g., European Patent Office, EPO) or international (PCT) filings to secure comprehensive coverage. The patent's claims may be aligned or expanded in subsequent filings to encompass broader chemical variations, formulations, or specific therapeutic methods.
Patent Family and Subsequent Applications
Preliminary searches indicate that the patent family may include filings in key markets such as EU countries and the US, reflecting strategic efforts to maximize protection. Future continuation patents could target specific salts, crystal forms, or combination therapies, creating a layered IP portfolio.
Enforcement and Licensing Potential
Given its therapeutic relevance and novelty, CY1113543 possesses considerable potential for licensing, especially if the claims withstand validity challenges. Enforcement would require precise patent clearance analyses to avoid infringing existing compounds or formulations.
Implications for Stakeholders
- Pharmaceutical Developers: The patent offers a solid IP foundation for developing niche therapeutics targeting autoimmune diseases with potentially reduced side effects.
- Generic Manufacturers: Due to the specific structural claims, there is a narrow margin for creating bioequivalent generics without licensing.
- Patent Attorneys: The patent's claims, especially regarding stereoisomers and formulations, serve as a precedent for drafting robust claims in similar chemical classes.
- Regulators and Patent Offices: This patent represents the ongoing evolution of medicinal chemistry, requiring careful assessment of inventive step amid a dense prior art landscape.
Conclusion
Patent CY1113543 embodies a strategic effort to secure exclusive rights over a novel class of heterocyclic compounds with therapeutic utility in inflammatory diseases. Its scope is carefully confined but broad enough to prevent minor structural modifications from circumventing protection. Its validity hinges on the inventive step over prior art, which is defensible given the demonstrated pharmacological advantages.
In the wider landscape, this patent signifies a targeted evolution within the anti-inflammatory chemical space, highlighting IC and R&D investments in optimizing molecule design for better bioavailability and reduced toxicity. Its success will depend on effective prosecution strategies, ongoing patent family development, and vigilant patent monitoring.
Key Takeaways
- The patent covers specific heterocyclic compounds with claimed therapeutic applications, supported by robust structural and functional data.
- Its scope extends to compounds, salts, formulations, and methods, creating broad protective umbrella but with clearly defined boundaries.
- Overlapping prior art necessitates strategic patent drafting to fortify validity, particularly through the inclusion of stereoisomers and derivatives.
- The patent landscape in the anti-inflammatory domain remains competitive, with CY1113543 offering a unique positioning based on pharmacokinetic improvements.
- Future strategic actions include expanding filings into key markets and pursuing additional patents on formulation, delivery methods, or combination therapies.
FAQs
1. What therapeutic indications does patent CY1113543 target?
The patent aims at treating autoimmune and inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriasis, utilizing specific heterocyclic compounds.
2. How broad are the claims in patent CY1113543?
The claims cover the compounds' chemical structures, their pharmaceutically acceptable salts and stereoisomers, and related pharmaceutical formulations and methods.
3. Are there any known prior art references that threaten the validity of this patent?
Yes, prior art discloses similar heterocyclic structures with anti-inflammatory activity; however, the specific structural features claimed in CY1113543 are considered inventive due to improved pharmacokinetic and safety profiles.
4. How does this patent fit within the global patent landscape?
It is part of a strategic patent family that may extend into regional and international filings to secure comprehensive market protection, especially in key jurisdictions such as the EU, US, and PCT.
5. What are the key strategic considerations for stakeholders regarding CY1113543?
Stakeholders should consider patent validity, potential for infringement, freedom-to-operate analyses, and opportunities for licensing or further patenting based on formulations and methods.
References
[1] Industry literature and prior patents cited in the patent application, illustrating related heterocyclic compounds and methods.
